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Foot insensitivity is associated with renal
function decline in patients with type 2
diabetes: a cohort study
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Abstract
Background: Identifying patients with diabetes at increased risk of chronic kidney disease (CKD) is essential to
prevent/slow the progression to end-stage renal disease (ESRD). CKD and diabetic peripheral neuropathy (DPN)
share common mechanisms. Hence, we aimed to examine the relationship between foot insensitivity and CKD in
patients with Type 2 diabetes.
Methods: A prospective observational cohort study in adults with Type 2 diabetes. Patients with ESRD were excluded.
Foot insensitivity was assessed using the 10-g monofilament test. Renal function was assessed using estimated glomerular
filtration rate (eGFR) based on the MDRD equation. Albuminuria was defined as the presence of urinary albumin/creatinine
ratio (ACR) >3.4 mg/mmol.
Results: Two hundred and twenty eight patients were recruited and followed-up for 2.5 years. One hundred
and ninety patients (83.4%) had eGFR ≥ 60 ml/min/1.73 m2. Seventy six (33.3%) patients had foot insensitivity
(i.e. abnormal monofilament test). Patients with foot insensitivity had lower eGFR and higher prevalence of
albuminuria compared to patients with normal monofilament test. After adjustment for age, gender, ethnicity,
diabetes duration, HbA1c, body mass index, insulin treatment, number of anti-hypertensives, history of peripheral vascular
disease, and baseline eGFR (R2 0.87), baseline foot insensitivity was associated with study-end eGFR (B =−3.551, p = 0.036).
Conclusions: Patients with Type 2 diabetes and foot insensitivity are at increased risk of eGFR decline. Identifying these
patients offers an opportunity to intensify metabolic and blood pressure control to prevent/retard the development of
CKD. Future studies of larger sample size and longer follow up from multiple centres are needed to assess the diagnostic
performance of our findings in predicting CKD development, and to compare the performance of the monofilament test
with albuminuria.
Keywords: Diabetic neuropathy, Chronic kidney disease, Diabetic nephropathy, Albuminuria, Estimated glomerular
filtration rate, Foot insensitivity, 10 g monofilament
Background
Chronic kidney disease (CKD) in diabetes is the most
common cause of end-stage renal disease (ESRD) and is
associated with high morbidity and mortality [1, 2]. CKD
in patients with diabetes progresses slowly, often starting
with microalbuminuria, which progresses to overt
proteinuria in 20–40% of patients and overall 20% of
patients will have progressed to ESRD within 20 years
after onset of overt proteinuria [1]. The speed of CKD
progression is variable and largely dependent on blood
pressure (BP), obesity, metabolic control and other fac-
tors such age, male sex and ethnicity [3, 4].
The pathogenesis of CKD is thought to be similar to
other microvascular complications and includes major
roles for hyperglycemia and hypertension promoting
increased oxidative and nitrosative stress and the activa-
tion of multiple pathways that lead to increased inflam-
mation and endothelial dysfunction [3]. In addition,
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hemodynamic changes occur as a result of the activation
of the renin–angiotensin–aldosterone (RAAS) and
endothelin systems, resulting in increased systemic and
intra-glomerular pressure, causing hyperfiltration and
albuminuria [3]. Despite attempts to improve metabolic
control and RAAS inhibition, CKD remains very com-
mon and many patients develop ESRD requiring renal
replacement therapy (RRT). Currently, albuminuria is
widely used to predict progression to ESRD but eGFR
decline may be the only manifestation of CKD progres-
sion in patients with diabetes without any evidence of
albuminuria in up to 30% of cases [5, 6].
In longitudinal studies of patients with type 2 diabetes,
we have previously identified obstructive sleep apnoea
(OSA) and cardiac autonomic neuropathy (CAN) as
novel predictors of eGFR decline [7, 8]. Clinically
evident DPN is common in patients with CAN and in
patients with OSA [9, 10] and as diabetic peripheral
neuropathy (DPN) shares many aspects of its pathogen-
esis with CKD, we hypothesised that foot insensitivity
may predict changes in renal function in patients with
Type 2 diabetes.
Hence, we have conducted a study to assess the
impact of foot insensitivity on eGFR in patients with
Type 2 diabetes. A secondary outcome was to assess the
impact of foot insensitivity on the development of albu-
minuria in patients with Type 2 diabetes.
Methods
We conducted a prospective observational cohort study
in White European and South Asian adults with type 2
diabetes. Patients were recruited between 2009 and 2010
and were followed until the end of 2012. Patients with
ESRD or significant chronic respiratory disorder were
excluded. Patients were recruited consecutively from the
diabetes clinics of a UK-based hospital (Birmingham
Heartlands Hospital). Patients were approached con-
secutively in the waiting area by the investigator or a
research nurse without any prior knowledge of their
medical condition. Consent was obtained and ethnicity
determined in accordance with the UK decennial census
by the study participants. The study was approved by
the Warwickshire Research Ethics Committee (REC
number 08/H1211/145) and funded by the National
Institute for Health Research (NIHR) in the UK. Previ-
ous publications related to this study population can be
found in [7, 8, 10, 11].
Foot insensitivity was defined as < 8 correct responses
to a 10-g monofilament applied to 10 foot locations [12].
The sensitivity and specificity of the monofilament test
to predict amputations or foot ulceration were 62 and
92% respectively [12]. Monofilament insensitivity was
found to be an independent predictor of foot ulceration
and amputations [13–15].
eGFR was calculated using the 4-variable MDRD equa-
tion [16]. The urinary albumin creatinine ratio (ACR) of
a single early morning urine measurement was used to
assess albuminuria as we have previously described [8].
Microalbuminuria was defined as ACR > 3.4 mg/mmol and
macroalbuminuria was defined as ACR ≥ 30 mg/mmol
[17–19]. Urine samples with evidence of urinary tract
infection were repeated when free from infection. ACR and
eGFR were measured at baseline and study-end. Study-end
measurements were taken during patient visits for follow-
up appointments at the diabetes clinic. eGFR and ACR
measurements during acute illness or following imaging
using contrast or from patients with significant haematuria,
or proteinuria without albuminuria were excluded.
All assessments in the study (renal function and
biochemical profiles) were conducted blinded to foot
insensitivity status.
Outcome measures and analyses
Data analysis was performed using SPSS 21.0 software
(SPSS Inc, Chicago, USA). Data distribution was examined
using histograms and the Shapiro-Wilk test. Data are pre-
sented as mean (SD) or median (IQR). Independent
continuous variables were compared using the Student’s
t-test or the Mann-Whitney test. Categorical variables
were compared using the Chi-squared test.
To assess the impact of foot insensitivity on eGFR
decline and albuminuria progression, only patients with
baseline and study-end measurements were used. For
the albuminuria progression analysis only patients free
of albuminuria at baseline were included. To account for
baseline differences, linear (for continuous outcomes)
and logistic (for dichotomous outcomes) regression were
used. Variables included in both the logistic and linear
regression models were based on those that differed
between patients with and without foot insensitivity and
the baseline value for outcome measure. The outcome
measures in the longitudinal analysis were the study-end
eGFR and progression to albuminuria. The “enter”
method was used in the regression analysis.
Residuals and collinearity were considered in assessing
fit of models to data. Sequentially removing variables
involved in multicollinearity had limited impact on
model estimates for the main exposure. Hence, final
models presented thus include variables based on those
that differed between patients with and without foot
insensitivity, regardless of the presence of collinearity.
A p-value < 0.05 was considered significant in all
statistical testing.
Results
Two hundred and twenty eight (228) patients were
recruited. Data regarding eGFR and the monofilament
status were available in all patients at baseline. Data
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regarding albuminuria were available in 215 (out of 228,
94.3%) patients at baseline. Follow up eGFR and albu-
minuria data were available in 225 (out of 228, 98.7%),
and 184 (out of 228, 80.1%) patients respectively.
Missing data during the follow up were not available on
the patients electronic records. The follow-up duration
was similar in patients with and without foot insensitiv-
ity (2.5 ± 0.6 vs. 2.5 ± 0.7 years, p = 0.4). For eGFR, 47.4%
(n = 108), 36.0% (n = 82), 15.4% (n = 35) and 1.3% (n = 3)
had values ≥ 90, 60–89, 30–59 and 15–29 ml/min/
1.73 m2 respectively.
Baseline analysis
Baseline demographics in relation to monofilament
status are summarised in Table 1.
Patients with foot insensitivity (i.e. abnormal monofila-
ment test) were older, had longer diabetes duration, were
more obese, had higher HbA1c and had more anti-
hypertensives compared to patients with normal mono-
filament test. Foot insensitivity was more common in
White Europeans than South Asians and more patients
with foot insensitivity had history of peripheral vascular
disease (PVD) and were prescribed insulin compared to
those with normal monofilament test.
The relationship between foot insensitivity and eGFR
and albuminuria is summarised in Table 2. Patients with
foot insensitivity had lower eGFR values and higher preva-
lence of albuminuria. There was no significant association
between foot insensitivity and macroalbuminuria.
Foot insensitivity and eGFR and albuminuria: follow-up
analysis
Data regarding the progression of eGFR, albuminuria,
and macroalbuminuria were available in 150 vs. 75, 83
vs. 29, and 112 vs. 50 patients without vs. with foot
insensitivity respectively.
The impact of foot insensitivity on albuminuria and
eGFR longitudinally is summarised in Tables 3 and 4. A
higher proportion of patients with foot insensitivity at
baseline progressed to develop albuminuria and macro-
albuminuria over the follow-up period compared to
patients with normal monofilament test. The eGFR
decline was also greater in patients with abnormal vs.
normal monofilament test. The impact of foot insensitiv-
ity on eGFR and the progression of albuminuria and
macroalbuminuria were more pronounced in South
Asians than White Europeans (Table 3).
After adjusting for age, gender, ethnicity, diabetes
duration, HbA1c, BMI, insulin treatment, number of anti-
hypertensives, history of PVD, and baseline eGFR (R2 0.87),
baseline foot insensitivity was associated with study-end
eGFR (B = −3.551, p = 0.036) (Table 4). Other independent
predictors of study-end eGFR were baseline eGFR
(B = 0.893, p < 0.001) and history of PVD (B = −10.044,
p = 0.001) (Table 4). Using change in eGFR between base-
line and study-end as the outcome measure instead of
study-end eGFR showed similar results (R2 0.161).
After adjustment for age, gender, ethnicity, diabetes
duration, HbA1c, BMI, insulin treatment, number of
anti-hypertensives, and history of PVD (Nagelkerke R2
0.328), baseline foot insensitivity was not significantly
associated with progression to albuminuria (OR 2.998,
95% CI 0.79–11.38, p = 0.107).
Table 1 Baseline demographics in relation to foot insensitivity
status
Monofilament¯ Monofilament+ P
n 152 76
Age (years) 54.9 ± 11.9 61.7 ± 11.2 <0.001
White Europeans 56 (36.8%) 46 (60.5%) 0.001
Male 80 (52.6%) 52 (68.4%) 0.023
Alcohol (drinks alcohol) 28 (18.4%) 17 (22.4%) 0.480
Smoking (never smoked) 98 (64.5%) 42 (55.3%) 0.178
Diabetes Duration (years) 10.9 ± 6.6 15.9 ± 8.5 <0.001
HBA1c (%) 8.1 ± 1.4 8.5 ± 1.6 0.045
Total cholesterol (mmol/l) 3.9 ± 1.0 3.9 ± 1.0 0.824
Triglycerides 2.0 ± 1.2 2.1 ± 1.3 0.605
Systolic BP (mmHg) 129.3 ± 15.4 131.7 ± 20.3 0.313
Diastolic BP (mmHg) 79.1 ± 9.7 76.3 ± 11.5 0.051
Mean arterial pressure 95.8 ± 10.2 94.8 ± 12.9 0.490
BMI (kg/m2) 32.7 ± 6.8 35.4 ± 10.4 0.045
Diabetic retinopathy (%)a 88 (58.7%) 59 (80.8%) 0.001
Foot ulceration (%) 1 (0.7%) 7 (9.2%) 0.002
IHD (%) 26 (17.1%) 20 (26.3%) 0.102
PVD (%) 4 (2.6%) 10 (13.2%) 0.002
Diabetic retinopathy (%) 88 (58.7%) 59 (80.8%) 0.001
Medication
Calcium Antagonist 36 (23.7%) 30 (39.5%) 0.013
Beta Blocker 30 (19.7%) 21 (27.6%) 0.177
Alpha Blocker 6 (3.9%) 13 (17.1%) 0.001
Diuretic 38 (25.0%) 36 (47.4%) 0.001
RAAS inhibitors 105 (69.1%) 53 (69.7%) 0.919
Anti hypertensives 116 (76.3%) 66 (86.8%) 0.062
No. of antihypertensives 1.0 (1.0–2.0) 2.0 (1.0–3.0) 0.001a
Lipid lowering treatment 129 (84.9%) 64 (84.2%) 0.897
Incretin-based treatment 28 (18.4%) 9 (11.8%) 0.204
OAD 142 (93.4%) 69 (90.8%) 0.476
Insulin 70 (46.1%) 50 (65.8%) 0.005
BMI body mass index, RAAS renin–angiotensin–aldosterone system, OAD oral
anti diabetes agents, IHD ischaemic heart disease, PVD peripheral vascular
disease. Monofilament¯: normal 10 g monofilament test; Monofilament+:
abnormal 10 g monofilament test i.e. foot insensitivity present
aDiabetic retinopathy data were available in 223 patients (150 with normal and
73 abnormal monofilament test). PVD, IHD and retinopathy data were based on
patients electronic records
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Using the last mentioned model but using progression to
macroalbuminuria as the outcome measure (Nagelkerke R2
0.499), showed that foot insensitivity was not associated
with the outcome (OR 9.37, 95%CI 0.93–94.61, p = 0.058).
HbA1c and PVD were significant predictors of the progres-
sion to macroalbuminuria.
Discussion
To our knowledge, this is the first study to examine the
relationship between foot insensitivity and the progres-
sion of eGFR and albuminuria in patients with Type 2
diabetes. Our results show that foot insensitivity was
associated with the decline in eGFR in patients with
Type 2 diabetes.
Whilst there appear to be no plausible mechanisms by
which foot insensitivity could have a direct/causal im-
pact on CKD in patients with diabetes, the two compli-
cations share common pathophysiological mechanisms.
These include increased oxidative stress, inflammation
and endothelial dysfunction. They also, share many risk
factors such as obesity, diabetes duration, older age, and
Table 2 Foot insensitivity and eGFR and albuminuria: Baseline
analysis
Variable Monofilament¯
N = 152a
Monofilament+
N = 76a
p value
eGFR (ml min−1 1.73 m−2) 89.5 ± 26.3 79.9 ± 26.0 0.010
Albuminuria 42 (29.2%) 34 (47.9%) 0.007
Macroalbuminuria 13 (9.0%) 11 (15.5%) 0.157
eGFR (ml min−1 1.73 m−2)
≥ 90 78 (51.3%) 30 (39.5%) 0.159
60–89 54 (35.5%) 28 (36.8%)
30–59 18 (11.8%) 17 (22.4%)
15–29 2 (1.3%) 1 (1.3%)
Monofilament¯: normal 10 g monofilament test
Monofilament+: abnormal 10 g monofilament test i.e. foot insensitivity present
aAlbuminuria data was available in 144 patients without and 71 with foot insensitivity
Table 3 The impact of foot insensitivity on eGFR and progression to albuminuria longitudinally
Variable Monofilament¯ Monofilament+ p value
Progression to albuminuria (Na = 83 vs. 29) 11 (13.3%) 10 (34.5%) 0.012
Progression to macroalbuminuria (Na = 112 vs. 50) 2 (1.8%) 7 (14.0%) 0.002
eGFR change (ml min−1 1.73 m−2) (Na = 150 vs. 75) −2.0 (−9.0 to 3.0) −7.0 (−17.0 to −2.0) 0.001
eGFR change as % of baseline eGFR (%) (Na = 150 vs. 75) −3.0 (−10.0 to 3.6)% −9.5 (−18.5 to −2.5)% <0.001
South Asians
Progression to albuminuria (Na = 50 vs. 8) 5 (10.0%) 3 (37.5%) 0.071
Progression to macroalbuminuria (Na = 67 vs. 20) 0 (0.0%) 4 (20.0%) 0.002
eGFR change (ml min−1 1.73 m−2)
(Na = 94 vs. 29)
−3.0 (−9.0 to 3.3) −10.0 (−17 to −3.0) 0.001
eGFR change as % of baseline eGFR (%) (Na = 94 vs. 29) −2.9 (−10.7 to 3.6)% −12.2 (−19.0 to −4.4) <0.001
White Europeans
Progression to albuminuria (Na = 33 vs. 21) 6 (18.2%) 7 (33.3%) 0.204
Progression to macroalbuminuria (Na = 45 vs. 30) 2 (4.4%) 3 (10.0%) 0.383
eGFR change (ml min−1 1.73 m−2)
(Na = 56 vs. 46)
−2.0 (−8.0 to 2.0) −5.5.0 (−15.0 to 1.3) 0.125
eGFR change as % of baseline eGFR (%) (Na = 56 vs. 46) −3.0 (−9.7 to 4.2)% −7.7 (−18.6 to −2.5)% 0.091
Monofilament¯: normal 10 g monofilament test; Monofilament+: abnormal 10 g monofilament test i.e. foot insensitivity present
aFor Monofilament¯ vs. Monofilament+ respectively
Table 4 The linear regression model for the association
between foot insensitivity and study-end eGFR
Variable Unstandardized
Regression coefficients
P value
Baseline eGFR
(ml min−1 1.73 m−2)
0.893 <0.001
Age (years) −0.078 0.327
Diabetes duration (years) −0.106 0.339
Gender (men vs. women) 2.075 0.180
HBA1c (%) −0.516 0.328
BMI (Kg/m2) −0.126 0.233
Insulin treatment (yes vs. no) −1.472 0.354
PVD (yes vs. no) −10.044 0.001
Number of anti hypertensives −0.528 0.399
Ethnicity (South Asians
vs. White Europeans)
1.433 0.389
Monofilament test
(abnormal vs. normal)
−3.551 0.036
R for the model = 0.931, R2 for the model = 0.866. The regression was
performed using the “Enter” method. eGFR estimated glomerular filtration rate,
BMI Body Mass Index, PVD Peripheral vascular disease; abnormal monofilament
test = foot insensitivity present
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hypertension [3, 20, 21]. Hence, it is not surprising that
these complications commonly co-exist, and this is
supported by the findings of our cross-sectional analysis.
In addition, DPN and CAN commonly co-exist and we
have shown previously that CAN predicts the eGFR
decline in patients with Type 2 Diabetes [7, 9]. We have
also previously shown an association between OSA and
foot insensitivity, and that OSA predicts eGFR decline in
patients with Type 2 diabetes [8, 10]. Hence, the
observed relationships between DPN and eGFR in our
study could be mediated, at least in part, by the relation-
ships between DPN and OSA and CAN.
In this study, we found that while foot insensitivity
was associated with changes in eGFR, it did not predict
the development of albuminuria. This could be related
to sample size as suggested by the odds ratios, but it
could also be that foot insensitivity identifies patients
with more advanced disease as the 10 g monofilament is
a test to identify feet at high risk of ulceration rather
than just neuropathy [12, 22].
The prevalence of foot insensitivity in our study was
higher in White Europeans compared to South Asians
which is consistent with previous studies from other
groups in the UK [23–25]. However, our results (Table 3)
show that while foot insensitivity was associated with
greater eGFR decline and greater progression to albu-
minuria in both South Asians and White Europeans, the
between group differences were greater and statistically
significant only in the South Asian group. The exact
reason for this observation is not clear from this study,
but one possible cause is that South Asians who develop
foot insensitivity have more severe vascular disease than
those with normal foot sensitivity in spite of foot
insensitivity being less common in South Asians vs.
White Europeans. Whereas, in White Europeans, there
might be other factors at play contributing to the decline
in eGFR such as obesity and OSA [10, 11].
In contrast to other diabetes related complications, in
spite of improvements in glycaemia and BP control as
well as RAAS inhibition, CKD leading to ESRD showed
no signs of reducing in prevalence in a recent study
from the US over a 20 year period [26]. Hence, it is im-
portant to identify patients who are at increased risk of
eGFR decline in order to implement preventative strat-
egies including intensive metabolic control. Currently,
ACR is the main biomarker used in clinical practice to
predict CKD and ESRD but 30% of patients still develop
ESRD without the development of albuminuria [5, 6].
Free light chains have also been proposed as a marker of
CKD and eGFR decline in patients with Type 2 diabetes,
but they are expensive to perform and need further
validation [27]. Our results demonstrate that simple, not
expensive and routinely performed foot examination can
identify patients at increased risk of eGFR decline.
Our study has also several strengths. It is the first to
prospectively examine the relationship between foot in-
sensitivity and eGFR as well as albuminuria and eGFR in
patients with type 2 diabetes. We used simple, inexpen-
sive, reproducible and routinely performed tests to predict
eGFR changes in this study. The study-population was
also well characterised with measurement of a wide range
of demographic, clinical and biochemical variables allow-
ing adjustment for a range of potential confounders.
Furthermore, the study included patients of both genders
and of both South Asian and White European ethnicity.
In addition, we focused on patients relatively early in the
course of CKD (as judged by baseline eGFR). This popula-
tion would be a prime target for treatments that might
slow the progression toward ESRD.
Our study has several limitations. We have used a
single ACR measurement instead of 2 out of 3 measure-
ments. However, the use of single, rather than multiple,
ACR measurement has been used in previous studies
and was shown to be adequate in epidemiological studies
[17–19]. The relatively small sample size and the missing
follow-up data for albuminuria, is a weakness. However,
no differences in characteristics of participants versus
patients lost to follow-up were observed. This was a
relatively small, single centre study so that the associa-
tions described should be viewed as hypothesis generat-
ing. Further, larger multi-centre studies are now
required to confirm whether the associations described
are correct and in turn to suggest further studies that
need to be done to look into mechanisms of the
described associations. In addition, despite adjustment
for multiple variables in the linear regression, we cannot
rule out the presence of other confounders that need to
be explored in future studies.
Conclusion
In summary, patients with Type 2 diabetes and foot in-
sensitivity are at increased risk of greater eGFR decline.
Identifying these patients might offer an opportunity to
intensify metabolic control and prevent the development
of CKD. Future studies of larger sample size and longer
follow up from multiple centres are needed to assess the
diagnostic performance of our findings in predicting
CKD development, and to compare the performance of
the monofilament test with albuminuria.
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